Phase 3 28-Week study with 24-Week and 52-week extension phases to evaluate efficacy and safety of Exenatide once weekly and Dapagliflozin versus Exenatide and Dapagliflozin matching placebo

Exclusion Criteria

• - FPG ≥280 mg/dL (15.6 mmol/L).
• - Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)
• - Clinically significant abnormal free T4 values or patients needing initiation or adjustment of thyroid treatment according to the investigator.
• - Abnormal thyroid stimulating hormone (TSH) value at Screening will be further evaluated by free T4.Patients with clinically significant abnormal free T4 values will be excluded.
• - Known active proliferative retinopathy.
• - History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1
• - History or presence of inflammatory bowel disease or other severe GI diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis.
• - History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded.